ChemoCentryx, Inc. Net Change in Cash
ChemoCentryx, Inc. reported Net Change in Cash of -$5.58 million for the 6-month period ending 2022-06-30, per its 10-Q filed 2022-08-08.
Discontinued › Cash Flow › Change in Cash
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect · last filed 2022-08-08
- ChemoCentryx, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2022-03-31 was -$9.40M, a 125.93% decline year-over-year.
- ChemoCentryx, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2021-03-31 was $36.25M, a 78.96% increase year-over-year.
- ChemoCentryx, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2020-03-31 was $20.26M, a 60.47% decline year-over-year.
- ChemoCentryx, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2019-03-31 was $51.24M.
- ChemoCentryx, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2021 was $17.68M.
- ChemoCentryx, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2020 was -$6.88M, a 156.54% decline from fiscal 2019.
- ChemoCentryx, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2019 was $12.17M.
- ChemoCentryx, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2018 was -$11.93M, a 142.62% decline from fiscal 2017.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 3 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 6 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 9 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 12 month |
|---|---|---|---|---|
| 2022-06-30 | -$5.58M 10-Q · filed 2022-08-08 | |||
| 2022-03-31 | -$9.40M 10-Q · filed 2022-05-10 | |||
| 2021-12-31 | $17.68M 10-K · filed 2022-03-01 | |||
| 2021-09-30 | $61.43M 10-Q · filed 2021-11-09 | |||
| 2021-06-30 | $44.91M 10-Q · filed 2022-08-08 | |||
| 2021-03-31 | $36.25M 10-Q · filed 2022-05-10 | |||
| 2020-12-31 | -$6.88M 10-K · filed 2022-03-01 | |||
| 2020-09-30 | $17.00M 10-Q · filed 2021-11-09 | |||
| 2020-06-30 | $294.03M 10-Q · filed 2021-08-09 | |||
| 2020-03-31 | $20.26M 10-Q · filed 2021-05-03 | |||
| 2019-12-31 | $12.17M 10-K · filed 2022-03-01 | |||
| 2019-09-30 | $8.91M 10-Q · filed 2020-11-09 | |||
| 2019-06-30 | $10.66M 10-Q · filed 2020-08-10 | |||
| 2019-03-31 | $51.24M 10-Q · filed 2020-05-11 | |||
| 2018-12-31 | -$11.93M 10-K · filed 2021-03-01 | |||
| 2018-09-30 | -$15.91M 10-Q · filed 2019-11-04 | |||
| 2018-06-30 | $28.73M 10-Q · filed 2019-08-05 | |||
| 2018-03-31 | -$9.47M 10-Q · filed 2019-05-06 | |||
| 2017-12-31 | $28.00M 10-K · filed 2020-03-10 | |||
| 2017-09-30 | $5.94M 10-Q · filed 2018-11-08 | |||
| 2017-06-30 | $9.48M 10-Q · filed 2018-08-09 | |||
| 2016-12-31 | -$799.00K 10-K · filed 2019-03-11 |